EUVIMEDEUVIMED entdecken
Crossref

Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer

Li Wang, Kai Yang, Xinxin Xie, Hailiang Wei, Pengli Wang, Shaohui Wang, Pengli Wang

Chemotherapy · 2025

DOI: 10.1159/000545185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, 2025. Verfasst von Li Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Cryosurgery. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aims to evaluate the efficacy and safety of cryoablation combined with pembrolizumab treatment versus cryoablation alone in patients with advanced non-small cell lung cancer (NSCLC).

Methods

This retrospective study was conducted from February 2018 to October 2021. A total of 90 patients with NSCLC (AJCC stage IIIB/IV) were included, with 36 patients receiving cryoablation combined with pembrolizumab (group A) and 54 patients receiving cryoablation alone (group B). The primary outcome measures included objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), immune responses, and adverse events serving as secondary endpoints. Risk factors for OS and PFS were identified using univariate and multivariate analyses.

Results

No treatment-related deaths were observed. Group A demonstrated a higher ORR (75.0% vs. 61.1%), longer median OS (28.1 months vs. 24.2 months), and longer median PFS (12.8 months vs. 8.4 months) compared to Group B. Additionally, group A showed significant increases in CD3+, CD4+, and CD8+ T cells, and elevated levels of interleukin-2, interleukin-6, TNF-β, and interferon-γ. The multivariate analysis showed the combination of cryoablation and pembrolizumab was an independent prognostic factor for OS and PFS.

Conclusions

Cryoablation combined with pembrolizumab significantly improves clinical outcomes in advanced NSCLC patients compared to cryoablation alone, highlighting the potential of this combination therapy in enhancing antitumor immunity and prolonging survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedCryosurgeryAntineoplastic Agents, ImmunologicalProgrammed Cell Death 1 ReceptorHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultCombined Modality TherapyAged, 80 and over

Stichwörter der Autor:innen

Advanced non-small cell lung cancerCombinationCryoablationPembrolizumabProgrammed cell death protein 1 inhibitor

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • College of Basic Medicine, Shaanxi University of Chinese Medicine, Xianyang, China.
  • Department of General Surgery, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.
  • Department of Oncology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China.

Zitieren

APA

Wang, L., Yang, K., Xie, X., Wei, H., Wang, P., Wang, S., & Wang, P. (2025). Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer. Chemotherapy. https://doi.org/10.1159/000545185

Vancouver

Wang L, Yang K, Xie X, Wei H, Wang P, Wang S, et al. Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer. Chemotherapy. 2025. doi:10.1159/000545185

BibTeX
@article{Wang2025,
  author = {Wang, Li and Yang, Kai and Xie, Xinxin and Wei, Hailiang and Wang, Pengli and Wang, Shaohui and Wang, Pengli},
  title = {Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer},
  journal = {Chemotherapy},
  year = {2025},
  doi = {10.1159/000545185}
}
Kostenlos starten →